Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 45Neoplasms 27Uterine Cervical Neoplasms 24Prostatic Neoplasms 21Carcinoma, Non-Small-Cell Lung 20Colorectal Neoplasms 19Stomach Neoplasms 18Carcinoma, Hepatocellular 16Multiple Myeloma 14Ovarian Neoplasms 11Recurrence 10Pancreatic Neoplasms 10Esophageal Squamous Cell Carcinoma 10Esophageal Neoplasms 9Leukemia, Myeloid, Acute 8Endometrial Neoplasms 8Lymphoma 7Lung Neoplasms 7Brain Neoplasms 7Liver Neoplasms 6Leukemia 6Disease 6Carcinoma, Ovarian Epithelial 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Papillomavirus Infections 5Colonic Neoplasms 5Urinary Bladder Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Unresectable Non-small Cell Lung Cancer × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡